02/07/09 Credit Suisse rates CSL as Outperform - The broker's latest review of the company's ISCOMATRIX vaccine adjuvant platform has it thinking that once the product hits the market (three to five years) it could increase valuation by $1.79 per share.
could csl disappoint on expectations?, page-24
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$303.81 |
Change
3.230(1.07%) |
Mkt cap ! $147.4B | |||
| Open | High | Low | Value | Volume |
| $304.48 | $304.99 | $303.13 | $46.25M | 152.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2 | $303.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $303.83 | 3 | 1 |
View Market Depth
| Last trade - 13.04pm 21/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |